February 20, 2024
1 min watch
Save
VIDEO: Topical treatments may be effective against moderate to severe atopic dermatitis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed data on roflumilast, which is already approved for psoriasis, as well as phase 3 data on tapinarof (Vtama, Dermavant).
“In a topical format you may be actually able to treat a wide variety of individuals that have more moderate-to-severe disease as opposed to the mild to moderate that we are really used to as well,” Chovatiya said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi and UCB.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.